ReviewTrends in molecular medicine2009
Strategies for targeted nonviral delivery of siRNAs in vivo.
Review in Trends in molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 113 citations in OpenAlex.
- Comparative Study of Functionalized Carbosilane Dendrimers for siRNA Delivery: Synthesis, Cytotoxicity, and Biophysical Properties.ACS omega · 2025Article
- Macrophage polarization in spinal cord injury repair and the possible role of microRNAs: A review.Heliyon · 2023Review
- The emerging potential of siRNA nanotherapeutics in treatment of arthritis.Asian journal of pharmaceutical sciences · 2023Review
- Alginate-Chitosan Hydrogels Containing shRNA Plasmid for Inhibition of CTNNB1 Expression in Breast Cancer Cells.Gels (Basel, Switzerland) · 2023Article
- Advancement and Applications of Platelet-inspired Nanoparticles: A Paradigm for Cancer Targeting.Current pharmaceutical biotechnology · 2023Review
- A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.International journal of nanomedicine · 2023Review
- CUL4The American journal of pathology · 2021Article
- Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Prospects of siRNA cocktails as tools for modifying multiple gene targets in the injured spinal cord.Experimental biology and medicine (Maywood, N.J.) · 2019Article
- Inhibition of coxsackievirus infection in cardiomyocytes by small dsRNA targeting its cognate coxsackievirus adenovirus receptor.The Indian journal of medical research · 2017Article
- Suppression of the expression of hypoxia-inducible factor-1α by RNA interference alleviates hypoxia-induced pulmonary hypertension in adult rats.International journal of molecular medicine · 2016Article
- Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.Biochemical and biophysical research communications · 2015Review
- MicroRNA delivery for regenerative medicine.Advanced drug delivery reviews · 2015Review
- Phage protein-targeted cancer nanomedicines.FEBS letters · 2014Review
- Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model.Stem cells international · 2014Article
- Article
- Nanomedicine for gene therapy.Drug delivery and translational research · 2013Article
- Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes.Nanomedicine : nanotechnology, biology, and medicine · 2013Article
- RNAi Therapeutics in Autoimmune Disease.Pharmaceuticals (Basel, Switzerland) · 2013Article
- SiRNA inhibits replication of Langat virus, a member of the tick-borne encephalitis virus complex in organotypic rat brain slices.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Silencing specific gene expression by RNA interference (RNAi) has rapidly become a standard tool for the reverse genetic analysis of gene functions. It also has tremendous potential for managing diseases for which effective treatment is currently unavailable or suboptimal. However, the poor cellular uptake of synthetic small interfering RNAs (siRNAs) is a major impediment for their clinical use. Great progress has been made in recent years to overcome this barrier, and several methods have been described for the in vivo delivery of siRNA. Moreover, the latest advances have focused on achieving targeted siRNA delivery restricted to relevant tissues and cell types in vivo. These approaches are expected to reduce the dose requirement as well as minimize siRNA-induced toxicities, thereby advancing the field of siRNA therapy towards clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.